Is there a correlation between HPV and urinary bladder carcinoma?

Biomedicine and Pharmacotherapy

Volumn 67, Issue 3, 2013, Pages 183-191

  Shaker, Olfat Gamil ^a   Hammam, Olfat A ^b   Wishahi, Mohamed M ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b THEODOR BILHARZ RESEARCH INSTITUTE   (Egypt)

^c Egypt   (Egypt)

Author keywords

Bladder carcinoma; Human papilloma virus; IHC; In situ hybridization; P21

Indexed keywords

PROTEIN P21; VIRUS DNA;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BLADDER BIOPSY; BLADDER CARCINOMA; BLADDER INJURY; CANCER STAGING; CONTROLLED STUDY; CYSTITIS; DNA CONTENT; DYSPLASIA; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMAL SQUAMOUS CELL CARCINOMA; SCHISTOSOMIASIS; SQUAMOUS CELL CARCINOMA; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; MALE; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84875522534     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.10.019     Document Type: Article

References (61)

1. Stein J.P., Grossfeld G.D., Ginsberg D.A., et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998, 160:645-659.
2. Helal T., Fadel M., El-Sayed N. Human papillomavirus and p53 expression in bladder cancer in Egypt: relationship to schistosomiasis and clinicopathologic factors. Path Oncol Res 2006, 12:173-178.
3. Khaled H.M., Bahnassi A.A., Zekri A.R. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol 2003, 21:334-341.
4. Anwar K., Naiki H., Nakakuki K., et al. High frequency of human papillomavirus infection in carcinoma of the urinary bladder. Cancer 1992, 70:1267-1273.
5. Lopez-Beltran A., Escudero A.L. Human papillomavirus and bladder cancer. Biomed Pharmacother 1997, 51(6-7):252-257. [Review].
6. Kelsey K.T., Hirao T., Hirao S., et al. TP53 alterations and patterns of carcinogen exposure in a US population-based study of bladder cancer. Int J Cancer 2005, 117(3):370-375.
7. Yu S.T., Wu M.M., Li L.M. Prevalence of human papillomaviruses 16 and 18 in transitional cell carcinoma of bladder. Chin Med J (Engl) 1993, 106(7):494-496.
8. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res 1989, 49(17):4677-4681. [Review].
9. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994, 186:131-156. [Review].
10. Barghi M.R., Hajimohammadmehdiarbab A., Moghaddam S.M., Kazemi B. Correlation between human papillomavirus infection and bladder transitional cell carcinoma. BMC Infect Dis 2005, 5:102.
11. Wolff E.M., Liang G., Jones P.A. Mechanisms of disease: genetic and epigenetic alterations that drive bladder cancer. Nat Clin Pract Urol 2005, 2(10):502-510. [Review].
12. Vince A., Lepej S.Z. Diagnostic methods and techniques in cervical cancer prevention Part II: molecular diagnostics of HPV infection. Med Glas Ljek komore Zenicko-doboj kantona 2010, 7(1):18-25. [Review].
13. Muñoz N., Bosch F.X., de Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527.
14. Blackburn E.H., Tlsty T.D., Lippman S.M. Unprecedented opportunities and promise for cancer prevention research. Cancer Prev Res (Phila) 2010, 3(4):394-402.
15. Lerner B. Bayesian fluorescence in situ hybridization signal classification. Artif Intell Med 2004, 30(3):301-316.
16. Unger E.R. In situ diagnosis of human papillomaviruses. Clin Lab Med 2000, 20(2):289-301. [vi. Review].
17. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998, 90(14):1072-1079.
18. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75(4):805-816.
19. Dulić V., Kaufmann W.K., Wilson S.J., et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 1994, 76(6):1013-1023.
20. Brugarolas J., Chandrasekaran C., Gordon J.I., Beach D., Jacks T., Hannon G.J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377(6549):552-557.
21. Niculescu A.B., Chen X., Smeets M., Hengst L., Prives C., Reed S.I. Effects of p21 (Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998, 18(1):629-643.
22. Ogryzko V.V., Wong P., Howard B.H. WAF1 retards Sphase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997, 17(8):4877-4882.
23. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1(8):639-649. [Review].
24. Fang J.Y., Lu Y.Y. Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J Gastroenterol 2002, 8(3):400-405. [Review].
25. Hall M.C., Li Y., Pong R.C., Ely B., Sagalowsky A.I., Hsieh J.T. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells. J Urol 2000, 163(3):1033-1038.
26. Al-Abadi H., Nagel R. Deoxyribonucleic acid content and survival rates of patients with transitional cell carcinoma of the bladder. J Urol 1994, 151(1):37-42.
27. Barclay I.D., Dabbagh L., Babiak J., Poppema S. DNA analysis (ploidy) of molar pregnancies with image analysis on paraffin tissue sections. Am J Clin Pathol 1993, 100(4):451-455.
28. Palmeira C.A., Oliveira P.A., Seixas F., Pires M.A., Lopes C., Santos L. DNA image cytometry in bladder cancer: state of the art. Anticancer Res 2008, 28(1B):443-450. [Review].
29. Wijkström H., Granberg-Ohman I., Tribukait B. Chromosomal and DNA patterns in transitional cell bladder carcinoma. A comparative cytogenetic and flow-cytofluorometric DNA study. Cancer 1984, 53(8):1718-1723.
30. Mostofi F., Sobin L., Torloni H. Histological typing of urinary bladder tumours. International classification of tumors 1973, Vol. 10. World Health Organization, Geneva.
31. Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. Pathology and genetics of tumors of the urinary system and male genital organs 2004, IARC Press, Lyon, France.
32. Shariat F.S., Kim G., Ptidis G., Ayala G.E., Lerner S.P. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003, 61(6):1140-1145.
33. El-Mawla N.G., El-Bolkainy M.N., Khaled H.M. Bladder cancer in Africa: update. Semin Oncol 2001, 28(2):174-178.
34. Freedman L., Edwards B., Ries L., Young J. Cancer Incidence in Four Member Countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) Compared with US SEER 2006, National Cancer Institute, NIH Pub. No. 06-5873, Bethesda, MD.
35. El-Bolkainy M.N., Mokhtar N.M., Ghoneim M.A., Hussein M.H. The impact of schistosomiasis on the pathology of bladder carcinoma. Cancer 1981, 48(12):2643-3248.
36. Muscheck M., Abol-Enein H., Chew K., et al. Comparison of genetic changes in schistosome-related transitional and squamous bladder cancers using comparative genomic hybridization. Carcinogenesis 2000, 21(9):1721-1726.
37. Badawi H., Helmy A., Tosson W., et al. Study of sTRAIL, TNF-β in serum and ultrastructural apototic changes in buffy coat cells in viral or chlamydial cystitis and cancer bladder cases. Egypt J Med Microbiol 2002, 2:877-888.
38. Khaled H.M., Bahnassi A.A., Zekri A.R., Kassem H.A., Mokhtar N. Correlation between p53 mutations and HPV in bilharzial bladder cancer. Urol Oncol 2003, 21(5):334-341.
39. Aglianò A.M., Gazzaniga P., Cervigni M., et al. Detection of human papillomavirus type 16 DNA sequences in paraffin-embedded tissues from the female urinary tract. Urol Int 1994, 52(4):208-212.
40. Bosch F.X., Lorincz A., Muñoz N., Meijer C.J., Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55(4):244-265. [Review].
41. Abdel Aziz M.T., Abdel Aziz M.Z., Atta H.M., et al. Screening for human papillomavirus (HPV) in egyptian females by the second-generation hybrid capture (HC II) test. Med Sci Monit 2006, 12(7):MT43-MT49.
42. Brentjens M.H., Yeung-Yue K.A., Lee P.C., Tyring S.K. Human papillomavirus: a review. Dermatol Clin 2002, 20(2):315-331. [Review].
43. Fioriti D., Pietropaolo V., Dal Forno S., Laurenti C., Chiarini F., Degener A.M. Urothelial bladder carcinoma and viral infections: different association with human polyomaviruses and papillomaviruses. Int J Immunopathol Pharmacol 2003, 16(3):283-288.
44. Youshya S., Purdie K., Breuer J., et al. Does human papillomavirus play a role in the development of bladder transitional cell carcinoma? A comparison of PCR and immunohistochemical analysis. J Clin Pathol 2005, 58(2):207-210.
45. Yu Z., Xia T., Xue Z. The detection of high-risk human papillomaviruses in papillary transitional cell carcinoma of urinary bladder. Zhonghua Wai Ke Za Zhi 1999, 37(6):369-371.
46. Kamel D., Pääkkö P., Pöllänen R., Vähäkangas K., Lehto V.P., Soini Y. Human papillomavirus DNA and abnormal p53 expression in carcinoma of the urinary bladder. APMIS 1995, 103(5):331-338.
47. De Gaetani C., Ferrari G., Righi E., et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridisation. J Clin Pathol 1999, 52(2):103-106.
48. Korkolopoulou P., Konstantinidou A.E., Thomas-Tsagli E., Christodoulou P., Kapralos P., Davaris P. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer. Appl Immunohistochem Mol Morphol 2000, 8(4):285-292.
49. Malkowicz S.B., Tomaszewski J.E., Linnenbach A.J., Cangiano T.A., Maruta Y., McGarvey T.W. Novel p21WAF1/CIP1 mutations in superficial and invasive transitional cell carcinomas. Oncogene 1996, 13(9):1831-1837.
50. Youssef R.F., Shariat S.F., Kapur P., et al. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. Hum Pathol 2011, 42(3):347-355.
51. Eissa S., Swelam M., Shaker Y., Abdel-Fattah M., Khalifa A. Expression of p21WAF1/CIP1 in bladder cancer: relation to schistosomiasis. IUBMB Life 1999, 48(1):115-119.
52. Cohen C. Image cytometric analysis in pathology. Hum Pathol 1996, 27(5):482-493.
53. El-Naggar A.K., Vielh P. Solid tumor DNA content analysis. Methods Mol Biol 2004, 263:355-370.
54. Alderisio M., Cenci M., Valli C., et al. Nm23-H1 protein, DNA ploidy and Sphase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder. Anticancer Res 1998, 18(6A):4225-4230.
55. Moureau-Zabotto L., Bouchet C., Cesari D., et al. Combined flow cytometry determination of Sphase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer. Breast Cancer Res Treat 2005, 91(1):61-71.
56. Kallioniemi O.P. Comparison of fresh and paraffin-embedded tissue as starting material for DNA flow cytometry and evaluation of intratumor heterogeneity. Cytometry 1988, 9(2):164-169.
57. Khafagy M.M., El-Bolkainy M.N., Mansour M.A. Carcinoma of the bilharzial urinary bladder. A study of the associated mucosal lesions in 86 cases. Cancer 1972, 30(1):150-159.
58. Shabaik A.S., Pow-Sang J.M., Lockhart J., Nicosia S.V. Role of DNA image cytometry in the follow-up of patients with urinary tract transitional cell carcinoma. Anal Quant Cytol Histol 1993, 15(2):115-123.
59. Pich A., Chiusa L., Comino A., Navone R. Cell proliferation indices, morphometry and DNA flow cytometry provide objective criteria for distinguishing low and high-grade bladder carcinomas. Virchows Arch 1994, 424(2):143-148.
60. Badawy A.A., El-Badrawy N.M., Mansy S.S., et al. Evaluation of colchicine with or without praziquantel therapy in the control of hepatic fibrosis in murine schistosomiasis. Pharmacol Res 1996, 33(6):319-325.
61. Schapers R.F., Smeets A.W., Pauwels R.P., van den Brandt P.A., Bosman F.T. Cytogenetic analysis in transitional cell carcinoma of the bladder. Br J Urol 1993, 72(6):887-892.